Cigna will stop covering GLP-1 weight-loss drugs in its employee health plan starting July 1, 2026 [1].
This move signals a potential shift in how health insurers manage the high costs of obesity treatments, as Cigna is one of the largest insurers in the U.S. The decision specifically impacts the company's own workforce rather than its broader commercial client base.
The policy change affects medications such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound [2]. These drugs, known as GLP-1 receptor agonists, have seen a surge in popularity for treating obesity and related metabolic conditions.
Cigna said the decision was driven by the rising costs of these specific medications [3]. The company did not provide a specific dollar amount for the expenditures, but the financial burden of providing these drugs to a large employee population became unsustainable for the internal plan.
The change takes effect on July 1, 2026 [1]. Employees currently using these medications will likely need to seek alternative payment methods or different treatment options as the deadline approaches.
While Cigna continues to offer various health services, the removal of these high-cost drugs from its employee plan highlights the ongoing tension between medical efficacy and corporate pharmacy spend. The company has not indicated if this internal policy will eventually be mirrored in the plans it sells to other corporate clients.
“Cigna will stop covering GLP-1 weight-loss drugs in its employee health plan”
Cigna's decision to remove GLP-1 coverage for its own staff serves as a bellwether for the broader insurance industry. As these drugs become more widely prescribed, the financial strain on payers is increasing. By cutting coverage for its own employees first, Cigna may be testing the feasibility of stricter utilization management or complete exclusions before applying similar restrictions to its external corporate customers.
